Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
1265 studies found for:    Open Studies | "Leukemia"
Show Display Options
Rank Status Study
21 Recruiting Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Condition: Leukemia
Interventions: Drug: Ibrutinib;   Drug: Rituximab
22 Recruiting A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL)
Condition: Leukemia
Interventions: Drug: Clofarabine;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Vincristine;   Drug: Rituximab;   Drug: Dexamethasone
23 Recruiting ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Procedure: Tumor sampling;   Biological: Constiutional DNA sampling
24 Recruiting A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Condition: Leukemia, B-Cell
Intervention: Drug: anti-CD19-CAR-T cells
25 Recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib
26 Recruiting Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
27 Recruiting Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab;   Biological: 10 mg/kg TRU-016 + Rituximab;   Biological: TRU-016 20 mg/kg + Obinutuzumab;   Biological: TRU-016 6-20 mg/kg + idelalisib + rituximab;   Biological: TRU-016 10-20 mg/kg + ibrutinib
28 Recruiting Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention:
29 Not yet recruiting Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Biological: NK Cells + Chemotherapy Starting
30 Recruiting Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Bendamustine;   Biological: Activated T-Cell Infusion;   Drug: Lenalidomide;   Behavioral: Phone Calls
31 Recruiting Regional Central Database Recording of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Practices evaluation
32 Recruiting First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Ibrutinib;   Drug: Allopurinol;   Drug: Valacyclovir
33 Recruiting Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: guadecitabine;   Drug: Treatment Choice (TC)
34 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention:
35 Recruiting Extramedullary Leukemia (EML) in Newly Diagnosed Acute Myeloid Leukemia (AML) is Underreported
Condition: Leukemia
Interventions: Drug: 18F-FDG;   Procedure: Whole Body Magnetic Resonance Imaging (MRI);   Drug: Gadolinium;   Procedure: Positron Emission Tomography/ Computed Tomography (PET/CT)
36 Recruiting A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Condition: Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
37 Recruiting Bosutinib in Elderly Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Bosutinib
38 Not yet recruiting D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Dasatinib;   Drug: Blinatumomab
39 Not yet recruiting Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Condition: Acute Lymphoblastic Leukemia, Pediatric
Interventions: Drug: Pegaspargase;   Drug: Erwinia asparaginase;   Drug: Cyclophosphamide;   Drug: CYTARABINE;   Drug: DASATINIB;   Drug: DEXAMETHASONE;   Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: ETOPOSIDE;   Drug: HYDROCORTISONE;   Drug: LEUCOVORIN CALCIUM;   Drug: MERCAPTOPURINE;   Drug: METHOTREXATE;   Drug: NELARABINE;   Drug: Vincristine
40 Recruiting A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, in Relapse;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: GO-203-2c;   Drug: GO-203-2c + Decitabine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.